Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

Sandra Bonache(CIBBIM-Nanomedicine), I. Esteban(Universitat Autònoma de Barcelona), Alejandro Moles‐Fernández(CIBBIM-Nanomedicine), Anna Tenés(Vall d'Hebron Hospital Universitari), Laura Duran-Lozano(CIBBIM-Nanomedicine), Gemma Montalban(CIBBIM-Nanomedicine), Vanessa Bach(CIBBIM-Nanomedicine), Estela Carrasco(Spanish Ovarian Cancer Research Group), Neus Gadea(Vall d'Hebron Hospital Universitari), Adrià López‐Fernández(Spanish Ovarian Cancer Research Group), Sara Torres‐Esquius(Spanish Ovarian Cancer Research Group), Francesco M. Mancuso(CIBBIM-Nanomedicine), Ginevra Caratù(CIBBIM-Nanomedicine), Ana Vivancos(CIBBIM-Nanomedicine), Noemí Tuset(Hospital Universitari Arnau de Vilanova), Judith Balmañà(Vall d'Hebron Hospital Universitari), Sara Gutiérrez‐Enríquez(Vall d'Hebron Institut de Recerca), Orland Dı́ez(Hebron University)
Journal of Cancer Research and Clinical Oncology
October 10, 2018
Cited by 65Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis